Search our Database of Scientific Publications and Authors

I’m looking for a

    249 results match your criteria Advances in Hematology [Journal]

    1 OF 5

    Study of Erythrocyte Indices, Erythrocyte Morphometric Indicators, and Oxygen-Binding Properties of Hemoglobin Hematoporphyrin Patients with Cardiovascular Diseases.
    Adv Hematol 2017 17;2017:8964587. Epub 2017 Jul 17.
    GBUZ RM "National Hospital for War Veterans", Saransk 430005, Russia.
    The current study investigates the functional state of erythrocytes and indices of the oxygen-binding capacity of hemoglobin in blood samples from healthy donors and from patients with coronary artery disease and myocardial infarction before and after treatment. It has been established that, in cardiovascular diseases, erythrocyte morphology and hemoglobin oxygen-transporting disorders are observed. Standard therapy does not result in the restoration of the structure and properties of erythrocytes. Read More

    Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia.
    Adv Hematol 2017 14;2017:6464972. Epub 2017 May 14.
    Department of Pharmacy, West Virginia University Medicine, Morgantown, WV, USA.
    Relapsed/refractory acute myeloid leukemia (RR-AML) is associated with poor prognosis and long-term disease-free survival requires allogeneic hematopoietic cell transplantation (allo-HCT). Limited data exists, regarding the optimal regimen to obtain remission prior to allo-HCT. Single agent high-dose cytarabine (10-12 doses administered every 12 hours) has been previously used as induction therapy. Read More

    Efficacy and Safety of Manual Partial Red Cell Exchange in the Management of Severe Complications of Sickle Cell Disease in a Developing Country.
    Adv Hematol 2017 11;2017:3518402. Epub 2017 May 11.
    Hematology, Cheikh Anta Diop University, BP 5005, Dakar, Senegal.
    Introduction: The realization of red cell exchange (RCE) in Africa faces the lack of blood, transfusion safety, and equipment. We evaluated its efficacy and safety in severe complications of sickle cell disease.

    Patients And Method: Manual partial RCE was performed among sickle cell patients who had severe complications. Read More

    The Evolution of Prognostic Factors in Multiple Myeloma.
    Adv Hematol 2017 21;2017:4812637. Epub 2017 Feb 21.
    King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
    Multiple myeloma (MM) is a heterogeneous hematologic malignancy involving the proliferation of plasma cells derived by different genetic events contributing to the development, progression, and prognosis of this disease. Despite improvement in treatment strategies of MM over the last decade, the disease remains incurable. All efforts are currently focused on understanding the prognostic markers of the disease hoping to incorporate the new therapeutic modalities to convert the disease into curable one. Read More

    Glucose-6-Phosphate Dehydrogenase Deficiency and Sickle Cell Trait among Prospective Blood Donors: A Cross-Sectional Study in Berekum, Ghana.
    Adv Hematol 2016 14;2016:7302912. Epub 2016 Sep 14.
    Department of Medical Laboratory Technology, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana.
    Background. Blood transfusion is a therapeutic procedure usually undertaken in patients with severe anaemia. In Ghana, severe anaemia is mostly due to malaria caused by severe Plasmodium falciparum infection, road traffic accidents, and haemoglobinopathy-induced acute haemolysis. Read More

    Autologous Graft-versus-Tumor Effect: Reality or Fiction?
    Adv Hematol 2016 22;2016:5385972. Epub 2016 Aug 22.
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
    In contrast to allogeneic hematopoietic stem cell transplantation, the current dogma is not an evidence of graft-versus-tumor effect in autologous hematopoietic stem cell transplantation; thus, it is assumed that autologous hematopoietic stem cell transplantation only relies on the high-dose chemotherapy to improve clinical outcomes. However, recent studies argue in favor of the existence of an autologous graft-versus-tumor without the detrimental complications of graft-versus-host disease due to the nonspecific immune response from the infused donor alloreactive immune effector cells in allogeneic hematopoietic stem cell transplantation. Herein, this paper reviews the clinical evidence of an autologous graft-versus-tumor effect based on the autograft collected and infused host immune effector cells and host immunity recovery after autologous hematopoietic stem cell transplantation affecting clinical outcomes in cancer patients. Read More

    Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies.
    Adv Hematol 2016 30;2016:3905907. Epub 2016 May 30.
    Department of Haematology, Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK; Department of Haematology, Guys and St. Thomas' NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK.
    Haematopoietic stem cell transplantation is a well-established treatment option for both hematological malignancies and nonmalignant conditions such as aplastic anemia and haemoglobinopathies. For those patients lacking a suitable matched sibling or matched unrelated donor, haploidentical donors are an alternative expedient donor pool. Historically, haploidentical transplantation led to high rates of graft rejection and GVHD. Read More

    Clinical Scenarios for Discordant Anti-Xa.
    Adv Hematol 2016 12;2016:4054806. Epub 2016 May 12.
    Servicio de Gastrocirugía, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, 06720 México, DF, Mexico.
    Anti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in which anti-Xa results can be bias. Read More

    Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance.
    Adv Hematol 2016 30;2016:6471901. Epub 2016 Apr 30.
    Bone Marrow Transplant Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
    The induction of specific tolerance, in order to avoid the detrimental effects of lifelong systemic immunosuppressive therapy after organ transplantation, has been considered the "Holy Grail" of transplantation. Experimentally, tolerance has been achieved through clonal deletion, through costimulatory blockade, through the induction or infusion of regulatory T-cells, and through the establishment of hematopoietic chimerism following donor bone marrow transplantation. The focus of this review is how tolerance has been achieved following combined bone marrow and kidney transplantation. Read More

    HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide.
    Adv Hematol 2016 7;2016:7802967. Epub 2016 Apr 7.
    Istituto di Ematologia, Universita' Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, Italy.
    The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloablative as well as myeloablative conditioning regimens, for bone marrow or peripheral blood grafts, for patients with malignant and nonmalignant disorders. Retrospective comparisons of HAPLO grafts with conventional sibling and unrelated donor grafts have been published and suggest comparable outcome. Read More

    Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow-Review of Published Literature.
    Adv Hematol 2016 28;2016:6950346. Epub 2016 Mar 28.
    Stem Cell Transplant Program, Henry Ford Hospital, Detroit, MI 48202, USA.
    Allogeneic hematopoietic stem cell transplantation (SCT) is often the only curative option for many patients with malignant and benign hematological stem cell disorders. However, some issues are still of concern regarding finding a donor like shrinking family sizes in many societies, underrepresentation of the ethnic minorities in the registries, genetic variability for some races, and significant delays in obtaining stem cells after starting the search. So there is a considerable need to develop alternate donor stem cell sources. Read More

    Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues.
    Adv Hematol 2016 24;2016:3467672. Epub 2016 Mar 24.
    Department of Blood and Marrow Transplantation, Dharamshila Hospital and Research Centre, Vasundhara Enclave, New Delhi 110096, India; Manashi Chakrabarti Foundation, Kolkata, India.
    Allogeneic hematopoietic stem cell transplantation (HSCT) remains a curative option for children with high risk and advanced acute leukemia. Yet availability of matched family donor limits its use and although matched unrelated donor or mismatched umbilical cord blood (UCB) are viable options, they fail to meet the global need. Haploidentical family donor is almost universally available and is emerging as the alternate donor of choice in adult patients. Read More

    Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies.
    Adv Hematol 2016 29;2016:5726132. Epub 2016 Feb 29.
    Division of Hematology-Oncology, Bone Marrow Transplant Service, Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue N., Worcester, MA 01655, USA.
    Allogenic hematopoietic cell transplantation (HSCT) is typically the preferred curative therapy for adult patients with acute myeloid leukemia, but its use has been reduced as a consequence of limited donor availability in the form of either matched-related donors (MRD) or matched-unrelated donors (MUD). Alternative options such as unrelated umbilical cord blood (UCB) transplantation and haploidentical HSCT have been increasingly studied in the past few decades to overcome these obstacles. A human leukocyte antigen- (HLA-) haploidentical donor is a recipient's relative who shares an exact haplotype with the recipient but is mismatched for HLA genes on the unshared haplotype. Read More

    Biochemical Markers of Bone Turnover in Patients with β-Thalassemia Major: A Single Center Study from Southern Pakistan.
    Adv Hematol 2016 23;2016:5437609. Epub 2016 Feb 23.
    Liaquat National Medical College, Karachi, Pakistan.
    Objectives. Skeletal complications in β-homozygous thalassemic patients are uncommon but often debilitating, even amongst children and adolescent patients with well maintained transfusion and chelation therapy. The aim is to evaluate the biochemical markers of bone turnover in regularly transfused thalassemic patients and its possible correlations with demographic data and hematological and biochemical markers. Read More

    Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph.
    Adv Hematol 2016 21;2016:7678901. Epub 2016 Feb 21.
    Biosciences Division, Emergent BioSolutions Incorporated, Winnipeg, MB, Canada R3T 5Y3; University of Manitoba, Winnipeg, MB, Canada R3T 2N2.
    The goal of these studies was to extensively characterize the first recombinant FIX therapeutic corresponding to the threonine-148 (Thr-148) polymorph, IXINITY (trenonacog alfa [coagulation factor IX (recombinant)]). Gel electrophoresis, circular dichroism, and gel filtration were used to determine purity and confirm structure. Chromatographic and mass spectrometry techniques were used to identify and quantify posttranslational modifications. Read More

    Seroprevalence of Hepatitis C, Hepatitis B, Cytomegalovirus, and Human Immunodeficiency Viruses in Multitransfused Thalassemic Children in Upper Egypt.
    Adv Hematol 2016 17;2016:9032627. Epub 2016 Feb 17.
    Department of Clinical Pathology, Faculty of Medicine, Sohag University, Sohag 82524, Egypt.
    Background. Frequent blood transfusions in thalassemia major children expose them to the risk of transfusion-transmitted infections (TTIs). The aim of this study was to estimate the prevalence of hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), and cytomegalovirus (CMV) in thalassemic children attending the Pediatrics Departments of both Sohag and Minia Universities of Upper Egypt, during the period from May 2014 to May 2015. Read More

    Relative Susceptibilities of ABO Blood Groups to Plasmodium falciparum Malaria in Ghana.
    Adv Hematol 2016 15;2016:5368793. Epub 2016 Feb 15.
    Department of Biomedical and Forensic Sciences, University of Cape Coast, Cape Coast, Ghana.
    The clinical outcome of falciparum malaria in endemic areas is influenced by erythrocyte polymorphisms including the ABO blood groups. Studies have reported association of ABO blood group to resistance, susceptibility, and severity of P. falciparum malaria infection. Read More

    Influence of Oxidative Stress on Stored Platelets.
    Adv Hematol 2016 2;2016:4091461. Epub 2016 Feb 2.
    Department of Biotechnology, Center for Post Graduate Studies, Jain University, No. 18/3, 9th Main, 3rd Block, Jayanagar, Bangalore 560011, India.
    Platelet storage and its availability for transfusion are limited to 5-6 days. Oxidative stress (OS) is one of the causes for reduced efficacy and shelf-life of platelets. The studies on platelet storage have focused on improving the storage conditions by altering platelet storage solutions, temperature, and materials. Read More

    Haploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic Disorders.
    Adv Hematol 2016 2;2016:1423493. Epub 2016 Feb 2.
    Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Durham, NC 27710, USA.
    Despite the advent of targeted therapies and novel agents, allogeneic hematopoietic stem cell transplantation remains the only curative modality in the management of hematologic disorders. The necessity to find an HLA-matched related donor is a major obstacle that compromises the widespread application and development of this field. Matched unrelated donors and umbilical cord blood have emerged as alternative sources of donor stem cells; however, the cost of maintaining donor registries and cord blood banks is very high and even impractical in developing countries. Read More

    Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide.
    Adv Hematol 2016 21;2016:9736564. Epub 2016 Jan 21.
    Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA 30342, USA.
    Relapse is the main cause of treatment failure after nonmyeloablative haploidentical transplant (haplo-HSCT). In an attempt to reduce relapse, we have developed a myeloablative (MA) haplo-HSCT approach utilizing posttransplant cyclophosphamide (PT/Cy) and peripheral blood stem cells as the stem cell source. We summarize the results of two consecutive clinical trials, using a busulfan-based (n = 20) and a TBI-based MA preparative regimen (n = 30), and analyze a larger cohort of 64 patients receiving MA haplo-HSCT. Read More

    Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation.
    Adv Hematol 2016 24;2016:4025073. Epub 2016 Jan 24.
    Department of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Outcomes of allogeneic hematopoietic stem cell transplantation (AHSCT) using HLA-half matched related donors (haploidentical) have recently improved due to better control of alloreactive reactions in both graft-versus-host and host-versus-graft directions. The recognition of the role of humoral rejection in the development of primary graft failure in this setting has broadened our understanding about causes of engraftment failure in these patients, helped us better select donors for patients in need of AHSCT, and developed rational therapeutic measures for HLA sensitized patients to prevent this unfortunate event, which is usually associated with a very high mortality rate. With these recent advances the rate of graft failure in haploidentical transplantation has decreased to less than 5%. Read More

    Comparison of Bone Mineral Density in Thalassemia Major Patients with Healthy Controls.
    Adv Hematol 2015 31;2015:648349. Epub 2015 Dec 31.
    Department of Radiology, PGIMER and Dr. RML Hospital, New Delhi 110001, India.
    Chronic hemoglobinopathies like thalassemia are associated with many osteopathies like osteoporosis. Methods. This observational study was carried out to compare the bone mineral density (BMD) in transfusion dependent thalassemics with that of healthy controls. Read More

    Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.
    Adv Hematol 2015 30;2015:612567. Epub 2015 Dec 30.
    Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.
    BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL specific tyrosine kinase inhibitors (TKIs). However, BCR-ABL TKIs do not allow completely eradicating both CML and ALL. Furthermore, ALL therapy is associated with much worse responses to TKIs than those observed in CML. Read More

    Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation.
    Adv Hematol 2015 2;2015:431923. Epub 2015 Dec 2.
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA.
    The implementation of high-dose posttransplantation cyclophosphamide (PTCy) has made HLA-haploidentical (haplo) blood or marrow transplantation (BMT) a cost effective and safe alternative donor transplantation technique, resulting in its increasing utilization over the last decade. We review the available retrospective comparisons of haplo BMT with PTCy and HLA-matched BMT in adults with hematologic malignancies. The examined studies demonstrate no difference between haplo BMT with PTCy and HLA-matched BMT with regard to acute graft-versus-host disease (aGVHD), nonrelapse mortality, and overall survival. Read More

    Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.
    Adv Hematol 2015 9;2015:848473. Epub 2015 Nov 9.
    Novartis Pharma AG, 4056 Basel, Switzerland.
    Few trial-based assessments of ruxolitinib in patients with lower-risk myelofibrosis (MF) have been conducted, and no studies have made such assessments in a real-world population. We assessed changes in spleen size and constitutional symptoms during ruxolitinib treatment using a retrospective, observational review of anonymized US medical record data of patients diagnosed with IPSS low-risk (n = 25) or intermediate-1-risk (n = 83) MF. The majority of patients were male (low risk, 60%; intermediate-1 risk, 69%). Read More

    Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness.
    Adv Hematol 2015 4;2015:167029. Epub 2015 Nov 4.
    Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Dr. M. H. Mari Gowda Road, Hombegowda Nagar, Bangalore, Karnataka 560030, India.
    Introduction. The incidence of Acute Myeloid Leukemia (AML) increases progressively with age and its treatment is challenging. This prospective case control study was undertaken to compare the safety, efficacy, and cost-effectiveness of decitabine with those of cytarabine in older patients with newly diagnosed AML who are not fit for intensive chemotherapy. Read More

    Profiling β Thalassemia Mutations in Consanguinity and Nonconsanguinity for Prenatal Screening and Awareness Programme.
    Adv Hematol 2015 21;2015:625721. Epub 2015 Oct 21.
    Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh 226014, India.
    Mutation spectrum varies significantly in different parts and different ethnic groups of India. Social factors such as preference to marry within the community and among 1st degree relatives (consanguinity) play an important role in impeding the gene pool of the disease within the community and so in society by and large. The present paper discusses the role of consanguinity in profiling of beta thalassemia mutation, and thus the approach for prenatal screening and prevention based awareness programme. Read More

    The Iron Status of Sickle Cell Anaemia Patients in Ilorin, North Central Nigeria.
    Adv Hematol 2015 15;2015:386451. Epub 2015 Oct 15.
    Department of Family Medicine, Kwara State Specialist Hospital, Sobi, 240001 Ilorin, Nigeria.
    Objectives. Sickle cell anaemia (SCA) is one of the commonest genetic disorders in the world. It is characterized by anaemia, periodic attacks of thrombotic pain, and chronic systemic organ damage. Read More

    Erythrocyte Catalase Activity in More Frequent Microcytic Hypochromic Anemia: Beta-Thalassemia Trait and Iron Deficiency Anemia.
    Adv Hematol 2015 7;2015:343571. Epub 2015 Oct 7.
    Instituto de Bioquímica Aplicada, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán (UNT), Balcarce 747, San Miguel de Tucumán, 4000 Tucumán, Argentina.
    Most common microcytic hypochromic anemias are iron deficiency anemia (IDA) and β-thalassemia trait (BTT), in which oxidative stress (OxS) has an essential role. Catalase causes detoxification of H2O2 in cells, and it is an indispensable antioxidant enzyme. The study was designed to measure erythrocyte catalase activity (ECAT) in patients with IDA (10) or BTT (21), to relate it with thalassemia mutation type (β (0) or β (+)) and to compare it with normal subjects (67). Read More

    Determinants of Overall and Progression-Free Survival of Nigerian Patients with Philadelphia-Positive Chronic Myeloid Leukemia.
    Adv Hematol 2015 7;2015:908708. Epub 2015 Sep 7.
    Department of Hematology and Immunology, Obafemi Awolowo University, Ile-Ife 234-220005, Nigeria ; Department of Hematology and Blood Transfusion, Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife 234-220005, Nigeria.
    Objective. The tyrosine kinase inhibitors have markedly changed the disease course for patients with Ph(+) and/or BCR-ABL1 (+) chronic myeloid leukemia (CML). This study was embarked upon to assess the long-term effects of imatinib therapy on survival in adult Nigerian patients with CML. Read More

    Frequency of Red Cell Alloimmunization and Autoimmunization in Thalassemia Patients: A Report from Eastern India.
    Adv Hematol 2015 6;2015:610931. Epub 2015 Sep 6.
    Department of Immunohematology & Blood Transfusion, MCH, Kolkata 700073, India.
    Introduction. Red blood cell (RBC) alloimmunization and autoimmunization remain a major problem in transfusion dependent thalassemic patients. There is a paucity of data on the incidence of RBC alloimmunization and autoimmunization in thalassemic patients from eastern part of India, as pretransfusion antibody screening is not routinely performed. Read More

    Predictors of Outcome and Severity in Adult Filipino Patients with Febrile Neutropenia.
    Adv Hematol 2015 3;2015:920838. Epub 2015 Sep 3.
    Department of Medicine, Philippine General Hospital, Taft Avenue, Ermita, 1000 Manila, Philippines.
    Aim. The study aimed to describe the profile of Filipino febrile neutropenia patients and to determine parameters associated with severe outcomes. Methods. Read More

    Corrigendum to "Characterization of Zebrafish von Willebrand Factor Reveals Conservation of Domain Structure, Multimerization, and Intracellular Storage".
    Adv Hematol 2015 19;2015:526854. Epub 2015 Aug 19.
    Department of Pediatrics, University of Michigan, Room 8301 Medical Science Research Building III, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-5646, USA.
    [This corrects the article DOI: 10.1155/2012/214209.]. Read More

    Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions.
    Adv Hematol 2015 18;2015:315289. Epub 2015 Aug 18.
    Department of Oncology, Prince Sultan Military Medical City, Saudi Arabia.
    Plasmablastic lymphoma (PBL) is an aggressive subtype of non-Hodgkin's lymphoma (NHL), which frequently arises in the oral cavity of human immunodeficiency virus (HIV) infected patients. PBL shows diffuse proliferation of large neoplastic cells resembling B-immunoblasts/plasmablasts, or with plasmacytic features and an immunophenotype of plasma cells. PBL remains a diagnostic challenge due to its peculiar morphology and an immunohistochemical profile similar to plasma cell myeloma (PCM). Read More

    Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies.
    Adv Hematol 2015 19;2015:431268. Epub 2015 Aug 19.
    Bayer HealthCare, 100 Bayer Boulevard, P.O. Box 915, Whippany, NJ 08981-0915, USA.
    Objectives. Prophylaxis regimens for severe hemophilia A allowing more flexible dosing while maintaining efficacy may improve adherence and decrease the cost of prophylaxis. Here, we compared the clinical effectiveness of once- or twice-weekly versus ≥3-times-weekly prophylaxis with sucrose-formulated recombinant factor VIII (rFVIII-FS) in a "real-world" practice setting. Read More

    Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence.
    Adv Hematol 2015 16;2015:920361. Epub 2015 Aug 16.
    Section of Thrombosis & Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    Vitamin K antagonists (VKA) and heparins have been utilized for the prevention and treatment of thromboembolism (arterial and venous) for decades. Targeting and inhibiting specific coagulation factors have led to new discoveries in the pharmacotherapy of thromboembolism management. These targeted anticoagulants are known as direct oral anticoagulants (DOACs). Read More

    Prospects of Vitamin C as an Additive in Plasma of Stored Blood.
    Adv Hematol 2015 9;2015:961049. Epub 2015 Aug 9.
    Center for Post Graduate Studies, Jain University, No. 18/3, 9th Main, 3rd Block, Jayanagar, Bangalore 560011, India.
    There is a dire necessity to improve blood storage and prolong shelf-life of blood. Very few studies have focused on oxidative stress (OS) in blood and its influence on plasma with storage. This study attempts to (i) elucidate the continuous changes occurring in plasma during storage through oxidant levels and antioxidant status and (ii) evaluate the influence of vitamin C (VC) as an additive during blood storage. Read More

    Association of ABO Blood Group Phenotype and Allele Frequency with Chikungunya Fever.
    Adv Hematol 2015 21;2015:543027. Epub 2015 Apr 21.
    Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand.
    Background. The objective of this study was to investigate the association of the ABO blood group phenotype and allele frequency with CHIK fever. Methods. Read More

    Impaired fibrinolysis in angiographically documented coronary artery disease.
    Adv Hematol 2015 23;2015:214680. Epub 2015 Feb 23.
    Faculty of Pharmacy, Federal University of Minas Gerais, Avenida Antonio Carlos 6627, 31270-901 Belo Horizonte, MG, Brazil.
    Impaired fibrinolysis may predispose to coronary artery disease (CAD). Hypofibrinolysis due to high levels of plasminogen activator inhibitor-1 (PAI-1) has been reported in CAD. A novel regulator of fibrinolytic activity, thrombin activatable fibrinolysis inhibitor (TAFI), has attracted attention in recent years. Read More

    RhD Specific Antibodies Are Not Detectable in HLA-DRB1(*)1501 Mice Challenged with Human RhD Positive Erythrocytes.
    Adv Hematol 2014 31;2014:470242. Epub 2014 Dec 31.
    The Canadian Blood Services, Canada ; Department of Laboratory Medicine and the Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond Street, Toronto, ON, Canada M5B 1W8 ; Departments of Medicine and Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada.
    The ability to study the immune response to the RhD antigen in the prevention of hemolytic disease of the fetus and newborn has been hampered by the lack of a mouse model of RhD immunization. However, the ability of transgenic mice expressing human HLA DRB1(*)1501 to respond to immunization with purified RhD has allowed this question to be revisited. In this work we aimed at inducing anti-RhD antibodies by administering human RhD(+) RBCs to mice transgenic for the human HLA DRB1(*)1501 as well as to several standard inbred and outbred laboratory strains including C57BL/6, DBA1/J, CFW(SW), CD1(ICR), and NSA(CF-1). Read More

    H. pylori May Not Be Associated with Iron Deficiency Anemia in Patients with Normal Gastrointestinal Tract Endoscopy Results.
    Adv Hematol 2014 31;2014:375915. Epub 2014 Dec 31.
    Department of Internal Medicine, Numune Training and Research Hospital, Yüreğir, 01240 Adana, Turkey.
    Background. The aim of this study was to investigate the association between iron deficiency anemia and H. pylori in patients with normal gastrointestinal tract endoscopy results. Read More

    Persistent Polyclonal B Cell Lymphocytosis B Cells Can Be Activated through CD40-CD154 Interaction.
    Adv Hematol 2014 14;2014:854124. Epub 2014 Dec 14.
    Centre Universitaire d'Hématologie et d'Oncologie de Québec, CHU de Québec, Hôpital de l'Enfant-Jésus, 1401 18ième rue, Québec, QC, Canada G1J 1Z4.
    Persistent polyclonal B cell lymphocytosis (PPBL) is a rare disorder, diagnosed primarily in adult female smokers and characterized by an expansion of CD19(+)CD27(+)IgM(+) memory B cells, by the presence of binucleated lymphocytes, and by a moderate elevation of serum IgM. The clinical course is usually benign, but it is not known whether or not PPBL might be part of a process leading to the emergence of a malignant proliferative disorder. In this study we sought to investigate the functional response of B cells from patients with PPBL by use of an optimal memory B cell culture model based on the CD40-CD154 interaction. Read More

    Aromatic Amines Exert Contrasting Effects on the Anticoagulant Effect of Acetaldehyde upon APTT.
    Adv Hematol 2014 8;2014:735751. Epub 2014 Dec 8.
    Department of Chemistry, Bowling Green State University, Bowling Green, OH 43403, USA.
    The pharmacological effects of amphetamine, procaine, procainamide, DOPA, isoproterenol, and atenolol upon activated partial thromboplastin time in the absence and presence of acetaldehyde have been investigated. In the absence of acetaldehyde, amphetamine and isoproterenol exhibit a procoagulant effect upon activated partial thromboplastin time, whereas atenolol and procaine display anticoagulant effects upon activated partial thromboplastin time. DOPA and procainamide do not alter activated partial thromboplastin time. Read More

    Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.
    Adv Hematol 2014 27;2014:986938. Epub 2014 Nov 27.
    Unidad de Medicina Interna, Sección de Enfermedades Infecciosas, Hospital Universitario Fundación Alcorcón, Calle Budapest 1, 28922 Madrid, Spain.
    Febrile neutropenia is one of the most serious complications in patients with haematological malignancies and chemotherapy. A prompt identification of infection and empirical antibiotic therapy can prolong survival. This paper reviews the guidelines about febrile neutropenia in the setting of hematologic malignancies, providing an overview of the definition of fever and neutropenia, and categories of risk assessment, management of infections, and prophylaxis. Read More

    Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma.
    Adv Hematol 2014 24;2014:652395. Epub 2014 Nov 24.
    Division of Hematology/Oncology, School of Medicine, University of Massachusetts, 55 Lake Avenue North, Worcester, MA 01655, USA.
    Autologous stem cell transplant (ASCT) is the standard of care in transplant-eligible multiple myeloma patients and is associated with significant improvement in progression-free survival (PFS), complete remission rates (CR), and overall survival (OS). However, majority of patients eventually relapse, with a median PFS of around 36 months. Relapses are harder to treat and prognosis declines with each relapse. Read More

    Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults Protocols.
    Adv Hematol 2014 17;2014:697675. Epub 2014 Nov 17.
    Department of Pediatrics Oncology and Hematological Malignancy, South Egypt Cancer Institute, Assiut University, Egypt.
    Objective. Several studies showed better outcome in adolescents and young adults with acute lymphoblastic leukemia (ALL) treated with pediatrics protocols than similarly aged patients treated with adults protocols, while other studies showed similar outcome of both protocols. We conducted this study to compare the outcome of our pediatrics and adults therapeutic protocols in treatment of adolescents ALL. Read More

    Evaluation of prothrombin time and activated partial thromboplastin time in hypertensive patients attending a tertiary hospital in calabar, Nigeria.
    Adv Hematol 2014 16;2014:932039. Epub 2014 Nov 16.
    Department of Medical Laboratory Science (Haematology and Blood Group Serology Unit), University of Calabar, PMB 1115, Calabar, Cross River State, Nigeria.
    Introduction. Several biomedical findings have established the effects of hypertension on haemostasis and roles of blood coagulation products in the clinical course of hypertension. Methods. Read More

    Determining risk factors of bleeding in patients on warfarin treatment.
    Adv Hematol 2014 9;2014:369084. Epub 2014 Nov 9.
    Department of Emergency Medicine, State Hospital, Balıkesir, Turkey.
    Background. Warfarin is a commonly used oral anticoagulant agent. The most common adverse effects of warfarin are bleeding complications. Read More

    1 OF 5